When was Sarcomatrix founded?

Sarcomatrix was founded in 2013.

Where is Sarcomatrix located?

Sarcomatrix is headquartered in Reno, United States. It is registered at 450 SINCLAIR ST, RENO, NV.

Is Sarcomatrix a funded company?

Sarcomatrix is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Sarcomatrix rank among its competitors?

Sarcomatrix ranks 13th amongst 14 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Elixirgen Therapeutics, which secured $4M in Oct, 2025.

Who are the top competitors of Sarcomatrix?

Sarcomatrix's top competitors include Entrada Therapeutics, Avidity Biosciences and Juvena Therapeutics. Among them, Elixirgen Therapeutics secured the most recent funding round in October, 2025.

Sarcomatrix - 2026 Company Profile, Team & Competitors

Company Details

Developer of therapeutics for muscle wasting diseases. It offers a drug pipeline which consist of α7β1 integrin activators and protein replacement therapies. It offers S-969, Sunitinib, and LAM 111 for muscular dystrophy.

Website: sarcomatrix.com
Email ID: *****@sarcomatrix.com
Phone Number: +1 **********
Registered Address: 450 SINCLAIR ST, RENO, NV

Key Metrics

Founded Year

2013

Location

Reno, United States

Stage

Unfunded

Ranked

13^th among 14 active competitors

Similar Companies

Entrada Therapeutics & 13 more

View Sarcomatrix's full profile

Sarcomatrix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Sarcomatrix Therapeutics Corp CIN: 0002017651 , United States, Active		-	-	-

Sarcomatrix has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sarcomatrix include Entrada Therapeutics, Avidity Biosciences and Juvena Therapeutics. Here is the list of Top 10 competitors of Sarcomatrix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Entrada Therapeutics 2016, Boston (United States), Public	Developer of the biologics-based platform to treat rare diseases	$175M	5AM Ventures, Roche & 11 others	69/100
2nd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	69/100
3rd	Juvena Therapeutics 2017, San Mateo (United States), Series B	Company developing protein based therapies for sarcopenia and muscle regeneration	$86.3M	Mubadala, Horizons Ventures & 23 others	61/100
4th	ARTHEx 2018, Valencia (Spain), Series B	Developer of oligonucleotide therapies for neuromuscular diseases	$93.6M	Invivo Ventures, Columbus Venture Partners ... & 11 others	57/100
5th	Vandria 2018, Lausanne (Switzerland), Series A	Developer of in-vitro screening platform for drug discovery and development	$30.7M	ND Capital, Dolby Family Ventures & 1 others	56/100
6th	Vita Therapeutics 2019, Baltimore (United States), Series B	Developer of therapeutic solutions for the treatment of muscular dystrophies	$83M	Cambrian BioPharma, Solve FSHD & 4 others	55/100
7th	Expansion Therapeutics 2016, San Diego (United States), Series B	Provider of a software system for the development of drugs	$140M	Sanofi Ventures, 5AM Ventures & 5 others	44/100
8th	Elixirgen Therapeutics 2012, Baltimore (United States), Series A	Developer of RNA therapeutics to treat multiple diseases	$29.4M	NIH, UTEC & 1 others	42/100
9th	Amplicore 2018, Cincinnati (United States), Seed	Provider of therapeutic solutions for musculoskeletal diseases	$6.82M	Photon Fund, Defense.gov & 4 others	39/100
10th	Hanugen 2017, Bengaluru (India), Seed	Developer of oligonucleotides to treat muscular dystrophy	-	BIRAC, C-CAMP & 2 others	32/100
13th	Sarcomatrix 2013, Reno (United States), Unfunded	Developer of therapeutics for muscle wasting diseases	-	-	23/100